SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-21-000089
Filing Date
2021-04-06
Accepted
2021-04-06 17:43:48
Documents
1
Period of Report
2021-04-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_161774532038498.html 4  
1 FORM 4 wf-form4_161774532038498.xml 4 13148
  Complete submission text file 0001725160-21-000089.txt   14746
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Bunker Kevin D. (Reporting) CIK: 0001807484 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 21810112